Leerink Partnrs Has Pessimistic View of ZNTL Q3 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Equities researchers at Leerink Partnrs lowered their Q3 2025 EPS estimates for Zentalis Pharmaceuticals in a report issued on Wednesday, August 6th. Leerink Partnrs analyst A. Berens now forecasts that the company will earn ($0.51) per share for the quarter, down from their prior estimate of ($0.43). The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($2.08) EPS, FY2026 earnings at ($1.88) EPS and FY2027 earnings at ($1.77) EPS.

ZNTL has been the subject of a number of other reports. HC Wainwright raised shares of Zentalis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 7th. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Saturday. Wells Fargo & Company reduced their price target on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, August 7th. Finally, Wedbush reissued a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th. Four equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Zentalis Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $8.20.

Zentalis Pharmaceuticals Trading Down 2.8%

ZNTL stock opened at $1.40 on Monday. Zentalis Pharmaceuticals has a one year low of $1.01 and a one year high of $5.44. The firm has a market capitalization of $101.00 million, a PE ratio of -0.62 and a beta of 1.71. The firm has a 50-day moving average of $1.38 and a two-hundred day moving average of $1.55.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.19.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Deutsche Bank AG raised its position in Zentalis Pharmaceuticals by 34.1% during the fourth quarter. Deutsche Bank AG now owns 42,804 shares of the company’s stock valued at $130,000 after acquiring an additional 10,873 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Zentalis Pharmaceuticals by 17.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 234,071 shares of the company’s stock valued at $372,000 after acquiring an additional 33,958 shares in the last quarter. BNP Paribas Financial Markets bought a new position in Zentalis Pharmaceuticals during the fourth quarter valued at approximately $534,000. Millennium Management LLC raised its position in Zentalis Pharmaceuticals by 8.1% during the fourth quarter. Millennium Management LLC now owns 957,563 shares of the company’s stock valued at $2,901,000 after acquiring an additional 71,477 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its position in Zentalis Pharmaceuticals by 169.2% during the fourth quarter. Russell Investments Group Ltd. now owns 60,021 shares of the company’s stock valued at $182,000 after acquiring an additional 37,726 shares in the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.